Glioblastoma survival

• Systematic review and epistemic meta-analysis to advance binomial AI-radiomics integration for predicting high-grade glioma progression and enhancing patient management
• Gene Therapy with Enterovirus 3 C Protease: A Promising Strategy for Various Solid Tumors
• A quantitative characterization of the heterogeneous response of glioblastoma U-87 MG cell line to temozolomide
• Unique Presentation of Glioblastoma With Acute Onset Symptomatology and Disease Recurrence
• Targeting the kynurenine pathway in gliomas: Insights into pathogenesis, therapeutic targets, and clinical advances
• KAT5 regulates neurodevelopmental states associated with G0-like populations in glioblastoma
• Tumor-associated long non-coding RNAs show variable expression across diffuse gliomas and effect on cell growth upon silencing in glioblastoma
• O (6)-methylguanine DNA methyltransferase (MGMT) expression in U1242 glioblastoma cells enhances in vitro clonogenicity, tumor implantation in vivo, and sensitivity to alisertib-carboplatin combination treatment

Advances in glioblastoma diagnosis and glioblastoma surgery mean that radical resections can be performed even in eloquent brain areas. However, patients not indicated for resection will experience a major reduction in life expectancy. Patients who underwent stereotactic biopsy and received some form of oncological treatment experienced slightly increased overall survival relative to patients with a natural disease course. Patients with favorable clinical factors reacted better to treatment ¹⁾

Glioblastoma overall survival.

Glioblastoma patients who were readmitted within 30 days had significantly shorter survival than nonreadmitted patients. Future studies that attempt to decrease readmissions and evaluate the impact of reducing readmissions on patient outcomes are needed ²⁾.

Despite advances in treatment, the median patient survival is 12 to 15 months ³⁾.

Glioblastoma progression.